Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Modi, S.; Saura, C.; Yamashita, T.; Park, Yeon-Hee; Kim, Sung-Bae; Tamura, K.; André, F.; Iwata, H.; Ito, Yoshinori; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.; Lee, K.; Hurvitz, S.; Cortés, J.; Lee, Caleb; Chen, Shuquan; Zhang, Lin; Shahidi, J.; Yver, A.; Krop, I.

doi:10.1056/NEJMoa1914510

Public

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shared by NobleBlocks on Dec 11, 2019 • 12:00 AM UTC

Authors:

S. Modi

C. Saura

T. Yamashita

Abstract

BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with a...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!